Top Markets
Coin of the day
RepliCel Life Sciences Inc. RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc.

RP
株式のランク #38777
Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a... Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.
株価
$0.01100905
最終同期: 2025-02-28
時価総額
$810.02K
変化(1日)
58.98%
変化(1年)
0.00%
CA
取引 RepliCel Life Sciences Inc. (RP)

カテゴリー

RepliCel Life Sciences Inc.(RP)の配当利回りの履歴
RepliCel Life Sciences Inc.(銘柄コード: RP)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
RepliCel Life Sciences Inc.(RP)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)